WuXi AppTec Co., Ltd.

Equities

603259

CNE1000031K4

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. 03:30:00 24/07/2024 am IST 5-day change 1st Jan Change
38.65 CNY -1.40% Intraday chart for WuXi AppTec Co., Ltd. +0.42% -46.88%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Nomura Adjusts WuXi AppTec's Price Target to 57.73 Yuan From 62.75 Yuan, Keeps at Buy MT
Nomura Adjusts WuXi AppTec's Price Target to HK$43.45 From HK$54.56, Keeps at Buy MT
WuXi AppTec Co., Ltd. Approves Cash Dividend Payment for the Financial Year Ended 31 December 2023, Payable on July 5, 2024 CI
Staff at drugmaker under U.S. scrutiny worked with Chinese military scientists RE
US lawmakers ask FBI for briefing on GenScript Biotech's links to China RE
US lawmakers ask FBI for briefing on GenScript Biotech's links to China RE
Wuxi Apptec Breaks Ground on Singapore R&D Site MT
Wuxi Apptec Completes Repurchase of Nearly 22 Million Shares with 1 Billion Yuan MT
Tranche Update on WuXi AppTec Co., Ltd.'s Equity Buyback Plan announced on March 8, 2024. CI
WuXi AppTec Co., Ltd.'s Equity Buyback announced on March 8, 2024, has closed with 21,593,780 shares, representing 0.74% for CNY 1,000 million. CI
WuXi AppTec Denies Being a Security Threat to US MT
HONG KONG SHARES OF WUXI APPTEC SET TO OPEN DOWN 2.1% AFTER US H… RE
US House committee advances bill to restrict BGI, WuXi AppTec RE
US HOUSE OVERSIGHT COMMITTEE VOTES TO ADVANCE LEGISLATION RESTRI… RE
US House committee to vote on bill to restrict BGI, WuXi AppTec RE
Chinese Stocks Muted as Investors Eye US Inflation Data, New Tariffs; Wuxi AppTec Rises Despite Biosecure Act Draft MT
US Congress Drafts Bill Asking Drug Firms to Unlink from Chinese Biotech Firms MT
WuXi Shares Volatile as U.S. Bill Revised to Set Deadline for Decoupling DJ
U.S. bill to restrict WuXi AppTec, other Chinese biotech cos revised to give more time to cut ties RE
Wuxi Apptec Co., Ltd. Proposes Final Cash Dividend Payment for the Financial Year Ended 31 December 2023 CI
Trade association survey shows 79% of US biotech companies contract with Chinese firms RE
Beijing, Fed Churn Asian Stock Markets in Sparse Trading MT
WuXi AppTec Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
WuXi AppTec Co., Ltd. Provides Earnings Guidance for the Full Year 2024 CI
Interest Rate Outlooks Quell Asian Stock Markets MT
Chart WuXi AppTec Co., Ltd.
More charts
Logo WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Net sales break down by activity as follows: - laboratory services (60.9%): small molecules discovery services, bioanalytical services, medical devices safety testing services, comprehensive manufacturing and testing services for cell and gene therapies, etc.; - CMO and CDMO services (31.9%): development of manufacturing processes, production of advanced intermediates and active pharmaceutical ingredients, formulation development and dosage drug product manufacturing, for preclinical and clinical trials, new drug application, and commercial supply of chemical drugs, etc.; - clinical research services (7.1%): project planning, clinical operation and monitoring and managements of phase I-IV clinical trials, medical device trials, etc.; - other (0.1%). Net sales are distributed geographically as follows: China (25.1%), Asia (4.1%), the United States (53.6%), Europe (16%) and other (1.2%) .
Employees
41,116
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
38.65CNY
Average target price
63.57CNY
Spread / Average Target
+64.48%
Consensus
  1. Stock Market
  2. Equities
  3. 603259 Stock
  4. News WuXi AppTec Co., Ltd.
  5. Nomura Adjusts Wuxi Apptec's Price Target to 139.96 Yuan From 113.43 Yuan, Keeps at Buy